Phase 2 Study With the Multi-Targeted Tyrosine-Kinase Inhibitor Pazopanib (GW786034) for Patients With Relapsed or Refractory Urothelial Cancer.
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2013
At a glance
- Drugs Pazopanib (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Therapeutic Use
- 05 Oct 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2009-017093-20).
- 11 Mar 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 26 Dec 2009 New trial record